Pharmacokinetics of orally administered melatonin in critically ill patients

Giovanni Mistraletti, Giovanni Sabbatini, Martina Taverna, Maria Adele Figini, Michele Umbrello, Paolo Magni, Massimiliano Ruscica, Elena Dozio, Roberto Esposti, Germana Demartini, Franco Fraschini, Rita Rezzani, Russel J. Reiter, Gaetano Iapichino

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Critically ill patients exhibit reduced melatonin secretion, both in nocturnal peaks and basal daytime levels. Oral melatonin supplementation may be useful for known sedative and antioxidant properties. Its early enteral absorption and daily pharmacokinetics were determined in two cohorts of six high-risk patients in this prospective trial. During their third and fourth Intensive Care Unit (ICU) day, they underwent two different sets of repeated blood samples to detect serum melatonin levels through radio-immuno-assay. Cohort 1: samples taken at 20:00, 20:45, 21:30, 24:00, 03:00, 06:00, 14:00, 20:00 to describe the daily pharmacokinetics. Cohort 2: 20:00, 20:05, 20:10, 20:20, 20:30, 20:45 to study the early absorption. On ICU day 3, endogenous levels were measured, while the absorption of exogenous melatonin was determined on ICU day 4 after administration, at 20:00, of 3 mg melatonin. All basal levels were below the expected values. Following enteral administration, pharmacological levels were already reached in 5 min, with a serum peak after 16 min (half-absorption time: 3 min 17 s). The maximum serum level observed was 11040 pg/mL and the disappearance rate indicated a half-elimination time of 1 hr 34 min. Serum melatonin levels decreased significantly after midnight; pharmacological levels were maintained up to 10 hr following administration. No excessive sleepiness was reported in this patient group. Critically ill patients exhibited reduced melatonin secretion, as reported in the literature. Despite the critical illness, the oral bioavailability was satisfactory: serum levels after oral administration showed basically unchanged intestinal absorption, while disappearance rate was slower than reported elsewhere in healthy volunteers.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalJournal of pineal research
Volume48
Issue number2
DOIs
StatePublished - Mar 1 2010

Keywords

  • Critically ill
  • Enteral absorption
  • Intensive care
  • Melatonin
  • Oral bioavailability
  • Pharmacokinetics
  • Radio-immuno-assay

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Pharmacokinetics of orally administered melatonin in critically ill patients'. Together they form a unique fingerprint.

  • Cite this

    Mistraletti, G., Sabbatini, G., Taverna, M., Figini, M. A., Umbrello, M., Magni, P., Ruscica, M., Dozio, E., Esposti, R., Demartini, G., Fraschini, F., Rezzani, R., Reiter, R. J., & Iapichino, G. (2010). Pharmacokinetics of orally administered melatonin in critically ill patients. Journal of pineal research, 48(2), 142-147. https://doi.org/10.1111/j.1600-079X.2009.00737.x